Invasive NSTEMI Strategy Shows No Benefit in Frail Patients - Takeaways - MDSpire
From the Journals

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management

  • By

  • Kathryn Wighton

  • May 6, 2026

  • 4 min

Share

  • 1

    The SENIOR-RITA trial evaluated frail patients aged 75+ with non-ST-elevation myocardial infarction.

  • 2

    Invasive strategy did not reduce cardiovascular death or myocardial infarction risk.

  • 3

    Patients with highest frailty levels had worse outcomes.

  • 4

    Primary outcome occurred in 38% of invasive vs. 29% of conservative care.

  • 5

    No significant differences in secondary outcomes were observed.

  • 6

    Results emphasize careful treatment decision-making in frail elderly patients.

  • 7

    Procedural complications were more frequent in frail patients but still uncommon.

Original Source(s)

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

  • by Kathryn Wighton

  • May 6, 2026

Related Content

Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma

A cohort study showed that patients with melanoma who received BRAF or MEK inhibitor therapy commonly experienced hypertension and mild cardiac dysfunction, supporting baseline cardiotoxicity risk str...

Most Decline Proactive Care Coordination

"Lack of effective communication across physicians is a health system problem."

Bereavement Tied to Higher Cardiovascular Risk

Acute post-loss period and pandemic conditions each amplified cardiovascular vulnerability in nationwide Swedish cohort study